Strategies to manage hepatitis C virus (HCV) disease burden

Wedemeyer, H.; Duberg, A.; Buti, M.; Rosenberg, W.; Frankova, S.; Esmat, G.; Ormeci, N.; Van Vlierberghe, H.; Gschwantler, M.; AKARCA, ULUS; Aleman, S.; Balik, I.; Berg, T.; Bihl, F.; Bilodeau, M.; Blasco, A.; Brandao Mello, C.; Bruggmann, P.; Calinas, F.; Calleja, J.; Cheinquer, H.; Christensen, P.; Clausen, M.; Coelho, H.; Cornberg, M.; Cramp, M.; Dore, G.; Doss, W.; El-Sayed, M.; ERGÖR, GÜL; Estes, C.; Falconer, K.; Felix, J.; Ferraz, M.; Ferreira, P.; Garcia-Samaniego, J.; Gerstoft, J.; Giria, J.; Goncales, F.; Guimaraes Pessoa, M.; Hezode, C.; Hindman, S.; Hofer, H.; Husa, P.; Idilman, R.; Kaberg, M.; Kaita, K.; Kautz, A.; Kaymakoglu, S.; Krajden, M.; Krarup, H.; Laleman, W.; Lavanchy, D.; Lazaro, P.; Marinho, R.; Marotta, P.; Mauss, S.; Mendes Correa, M.; Moreno, C.; Muellhaupt, B.; Myers, R.; Nemecek, V.; Ovrehus, A.; Parkes, J.; Peltekian, K.; Ramji, A.; Razavi, H.; Reis, N.; Roberts, S.; Roudot-Thoraval, F.; Ryder, S.; Sarmento-Castro, R.; Sarrazin, C.; Semela, D.; Sherman, M.; Shiha, G.; Sperl, J.; Starkel, P.; Stauber, R.; Thompson, A.; Urbanek, P.; Van Damme, P.; van Thiel, I.; Vandijck, D.; Vogel, W.; Waked, I.; Weis, N.; Wiegand, J.; Yosry, A.; Zekry, A.; Negro, F.; Sievert, W.; Gower, E.

doi:10.1111/jvh.12249

Strategies to manage hepatitis C virus (HCV) disease burden

Atıf İçin Kopyala

Wedemeyer H., Duberg A. S., Buti M., Rosenberg W. M., Frankova S., Esmat G., ...Daha Fazla

JOURNAL OF VIRAL HEPATITIS, cilt.21, ss.60-89, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21
Basım Tarihi: 2014
Doi Numarası: 10.1111/jvh.12249
Dergi Adı: JOURNAL OF VIRAL HEPATITIS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.60-89
Anahtar Kelimeler: diagnosis, epidemiology, HCV, mortality, treatment, scenarios, prevalence, incidence, hepatitis C, disease burden, SUSTAINED VIROLOGICAL RESPONSE, SINGLE-SOURCE OUTBREAK, PEGINTERFERON ALPHA-2B, HEPATOCELLULAR-CARCINOMA, TRIPLE THERAPY, TELAPREVIR, INFECTION, POPULATION, PREVALENCE, RIBAVIRIN
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.